95 related articles for article (PubMed ID: 32200511)
1. Ten-year prospective evaluation of whole-body cancer screening with multiple modalities including [
Nishizawa S; Kojima S; Okada H; Shinke T; Torizuka T; Teramukai S; Fukushima M
Ann Nucl Med; 2020 May; 34(5):358-368. PubMed ID: 32200511
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
[TBL] [Abstract][Full Text] [Related]
3. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
6. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
9. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure.
Ghotbi N; Iwanaga M; Ohtsuru A; Ogawa Y; Yamashita S
Asian Pac J Cancer Prev; 2007; 8(1):93-7. PubMed ID: 17477780
[TBL] [Abstract][Full Text] [Related]
10. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
11. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Kojima S; Zhou B; Teramukai S; Hara A; Kosaka N; Matsuo Y; Suzuki H; Torigoe S; Suzuki T; Uno K; Fukushima M
Eur J Cancer; 2007 Aug; 43(12):1842-8. PubMed ID: 17614273
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
Sasamori H; Uno K; Wu J
Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
[TBL] [Abstract][Full Text] [Related]
13. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
15. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
16. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening.
Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
Ann Nucl Med; 2007 Jan; 21(1):65-72. PubMed ID: 17373338
[TBL] [Abstract][Full Text] [Related]
17. Cancer screening with FDG-PET.
Ide M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
[TBL] [Abstract][Full Text] [Related]
18. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
